Executive Management

Brenda Reynolds, Executive Chairman

Brenda Reynolds was a founder and the Chief Operating Officer of Convergence Pharmaceuticals. Prior to that Brenda was COO of PowderMed Ltd.; Vice President of Portfolio & Programme Management at PowderJect Pharmaceuticals plc. Brenda has also held a number of senior positions across the healthcare sector including roles at Pfizer, Scotia Holdings PLC, G D Searle and is currently Director of iQur and BQR Consulting Ltd and a member of the BIA Board. Brenda holds a degree in Toxicology, and is a Chartered Director and Fellow of the IOD.

Manjit Rahelu, Chief Business Officer

Manjit is a senior Healthcare/Pharmaceutical executive, with a strong science background and broad based technical, commercial and financial experience gained over two decades in the industry. He was the VP Business Development of Convergence Pharmaceuticals Ltd. His multifunctional, international expertise was gained in blue chip (Pfizer, Sanofi, and Novartis), mid-sized (UCB) and Biotech companies with leadership and functional experience in HQ and country affiliate roles. He brings business development expertise in M&A and product focused licensing on both the buy and sell side.

Zahid Ali, Chief Scientific Officer

Zahid joined Calchan from Pfizer Neusentis in May 2015 where he was a Senior Director of clinical research specialising in the early development of novel analgesic assets. Zahid has almost 20 years of experience in Pharmaceutical pain and inflammation research gained at Pfizer, Glaxo SmithKline and Merck Sharp and Dohme. During that time he has worked across multiple ion channel and GPCR targets as well as having responsibility for translational strategies, pre-competitive R&D with industry and academic partners and working across multiple in-licensing opportunities. Whilst at both Pfizer and GlaxoSmithKine he has worked closely and extensively with late stage development and commercial colleagues to identify the development path and commercial viability of novel analgesic assets. Zahid gained his PhD in the role of serotonergic mechanisms in spinal nociceptive processing from Cardiff University, UK and completed a postdoctoral fellowship in neuropathic pain mechanisms in the laboratories of Richard Meyer, James Campbell and Srinivasa Raja at the Johns Hopkins University, Baltimore, USA prior to joining the industry.

Karl Gibson, Director Medicinal Chemistry

Karl has a deep expertise in Medicinal Chemistry. Having completed his PhD at Cambridge University, Karl joined Merck Sharpe and Dohme where he led multiple early stage pain and neuroscience programs. Karl then moved to Pfizer where he gained increased levels of management and project responsibility. Karl is a co-founder of Sandexis (2011-16) and alongside his Sandexis activities has taken on ASK1 project responsibilities for Calchan since 2015.